About 80,000 people in Switzerland are forced to expect a seizure at any time, which can have a major impact on their everyday lives. In 2022, Life Science Communication launched an online campaign for people with epilepsy on behalf of Epi-Suisse.

The Italian company Angelini Pharma had developed an innovative therapy for people with focal epilepsy, which greatly facilitates their lives. Life Science Communication is supporting Angelini Pharma in terms of medical communication with the organization and execution of advisory boards, medical writing, coordination of online training, and the development of training and patient information. Together, we are committed to improving the lives of people with epilepsy.